SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-24-018736
Filing Date
2024-02-22
Accepted
2024-02-22 16:02:42
Documents
95
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 10-K ntla-20231231.htm   iXBRL 10-K 3140776
2 EX-3.1 ntla-ex3_1.htm EX-3.1 78248
3 EX-10.23 ntla-ex10_23.htm EX-10.23 76358
4 EX-21.1 ntla-ex21_1.htm EX-21.1 4643
5 EX-23.1 ntla-ex23_1.htm EX-23.1 5699
6 EX-31.1 ntla-ex31_1.htm EX-31.1 12268
7 EX-31.2 ntla-ex31_2.htm EX-31.2 12057
8 EX-32.1 ntla-ex32_1.htm EX-32.1 9562
9 EX-97.1 ntla-ex97_1.htm EX-97.1 44018
10 GRAPHIC img109078928_0.jpg GRAPHIC 101328
11 GRAPHIC img109078928_1.jpg GRAPHIC 240455
  Complete submission text file 0000950170-24-018736.txt   13146262

Data Files

Seq Description Document Type Size
12 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT ntla-20231231.xsd EX-101.SCH 1721028
97 EXTRACTED XBRL INSTANCE DOCUMENT ntla-20231231_htm.xml XML 2054558
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Filer) CIK: 0001652130 (see all company filings)

IRS No.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-37766 | Film No.: 24664614
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)